Notes on the Design of Bioequivalence Study: Isoniazid

Notes on the design of bioequivalence studies with products invited for submission to the WHO Prequalification Team – Medicines (PQT/MED) are issued to aid manufacturers with the development of their product dossier. Deviations from the approach suggested below can be considered acceptable if justified by sound scientific evidence.


Below, additional specific guidance is provided on the invited immediate release products containing isoniazid.

Pharmacokinetics of isoniazid

After oral administration isoniazid produces peak blood levels within 1 to 2 hours. Ingestion of isoniazid with food may reduce its absorption. Isoniazid should be administered preferably on an empty stomach at least 30 minutes before a meal or 2 hours after a meal. Isoniazid is metabolised primarily by acetylation and dehydrazination. The rate of acetylation is genetically determined. The elimination half-life in fast acetylators is 0.5 - 1.6 h and in slow acetylators is 2 – 5 h approximately.

Guidance for the design of bioequivalence studies

Taking into account the pharmacokinetic properties of isoniazid the following guidance with regard to the study design should be taken into account:

**Design:** A single-dose crossover design is recommended.

**Dose:** As the EoI includes 300 mg scored tablets or capsules and 100 mg scored and dispersible tablets, the bioequivalence study should be conducted with the highest strength if the conditions for the biowaiver of the additional strength are fulfilled. Otherwise, a study should be conducted for each strength.

**Fasted/fed:** As isoniazid should be taken on an empty stomach, a fasted state study should be conducted.

**Subjects:** Healthy adult subjects should be recruited. It is not necessary to include patients in the bioequivalence study.

**Parent or metabolite data for assessment of bioequivalence:** The parent drug is considered to best reflect the biopharmaceutical quality of the product. Therefore, bioequivalence for isoniazid should be based on the determination of the parent compound.
**Sample size:** Isoniazid $C_{\text{max}}$ seems to be moderately variable (15 – 29 %). These data may facilitate the calculation of a sufficient sample size for a crossover bioequivalence study.

**Washout:** Taking into account the elimination half-life of isoniazid in healthy volunteers of 0.5 – 5 hours, a washout period of 7 days is considered sufficient to prevent carry over.

**Blood sampling:** The blood sampling should be intensive for the first three hours after administration to properly characterize the $C_{\text{max}}$ of isoniazid. It is not necessary to take blood samples beyond 12 hours for the characterization of the pharmacokinetics of immediate release products containing isoniazid. For example, blood samples can be taken pre-dose and at 0.17, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 2.75, 3.00, 3.25, 3.50, 3.75, 4.00, 5.00, 6.00, 8.00, 12.00 hours.

**Analytical considerations:** Information currently available indicates that it is possible to measure isoniazid in human plasma using LC-MS/MS analytical methodology. The bioanalytical method should be sufficiently sensitive to detect concentrations that are 5% of the $C_{\text{max}}$ in most profiles of each formulation (test or comparator).

**Statistical considerations:** The data for isoniazid should meet the following bioequivalence standards in a single-dose crossover design study:

- The 90% confidence interval of the relative mean $AUC_{0-t}$ of the test to comparator product should be within 80.00 – 125.00%.

- The 90% confidence interval of the relative mean $C_{\text{max}}$ of the test to comparator product should be within 80.00 – 125.00%.